Avista Capital Partners in partnership with Dana Holdings announced the completion of its acquisition of Kramer Laboratories, a marketer of over-the-counter foot care and specialty cough products. 

Kramer’s portfolio includes leading foot care brands such as The Original Fungi-Nail Toe & Foot and HC Max, as well as the Safetussin, brand of specialty cough solutions.

David Burgstahler, president and co-managing partner of Avista, said, “We are excited to welcome Kramer to our healthcare portfolio. The Company has a strong foundation, with well-established brands, national distribution and an experienced management team. We look forward to working with the Kramer team and leveraging Avista’s expertise in the healthcare sector to support the Company’s future development and expansion.”

Dana’s Managing Member, Joe Falsetti, said, “We are delighted to partner with Avista Capital Partners and the entire Kramer organization. We are excited about the prospects for the Kramer brands and look forward to working with Avista and the Kramer team to create long-term value.”

Rick Kornhauser, chief executive officer of Kramer, said, “We are thrilled  to partner with Avista and Dana and look forward to working together to capture the substantial growth opportunities ahead. A partnership with Avista and Dana will infuse Kramer with valuable financial and business expertise that will create significant benefits for our customers, account partners and employees.”

Robert O’Neil, an Avista operating executive, will serve as chairman of the Board of Directors of Kramer. Mr. O’Neil has more than 35 years of operational and strategic business leadership experience. Prior to Avista, Mr. O’Neil served as worldwide vice president of Business Development for the Johnson & Johnson’s Consumer Group of Companies.